ADC Therapeutics SA
ADCTHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ADC Therapeutics SA focuses on Drug Manufacturers - Specialty & Generic services and products. ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. The $166.0M market capitalization puts ADCT squarely in micro-cap range for its industry. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Market Cap
$166.0M
Beta
1.85
P/E (TTM)
—
P/E (Fwd)
-0.87
EPS (TTM)
$-0.58
EPS (Fwd)
$-1.49
ROE
—
ROA
-19.6%
Cash
$219.1M
Total Debt
$438.2M
Free CF
-$68.1M
52W Change
-57.9%
Annual Financials
Cash vs Debt
Where ADCT stands vs its 150-day and 200-day moving averages
As of the August 7, 2026 close, ADCT finished 62.83% below its 150-day moving average ($3.04) and 65.55% below its 200-day moving average ($3.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADCT overbought or oversold?
At the August 7, 2026 close, ADCT's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ADCT has $219.1M in cash with $438.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$68.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been uneven over recent years, ranging from $209.9M to $81.4M.
ADC Therapeutics SA's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ADCT.